Scholars@Duke
Quinn Ostrom

Quinn Ostrom

Associate Professor in Neurosurgery
Neurosurgery, Neuro-Oncology
571 Research Drive, MSRB-1, Rm 442, Durham, NC 27710

Scholarly Works - Conferences

Assessing loneliness in glioblastoma patients and caregivers using a nationwide survey.

Conference Journal of Clinical Oncology · June 1, 2026 12097Background: Loneliness is associated with poorer health outcomes and quality of ... Full text Cite

Communication of tumor testing and molecular results to patients and caregivers in glioblastoma: A national survey.

Conference Journal of Clinical Oncology · June 1, 2026 e14041Background: Tumor testing and molecular characterization are essential for pers ... Full text Cite

Abstract 1338: DPP-4: A CD8+ T cell metabolic checkpoint and cancer immunotherapy target.

Conference Cancer Research · April 3, 2026 AbstractExhaustion of CD8+ T cells in the tumor microenvironment is intertwined with metabolic dysfunction. Thus, metabolic reinvigoration of T cells is a promising cancer immunotherapy strategy. Here, we ... Full text Cite

Abstract 5061: Allele frequency variation in people of European and admixed African ancestry in the United States do not fully explain incidence differences in adult-type diffuse glioma

Conference Cancer Research · April 3, 2026 AbstractBackgroundGlioma is a heterogeneous group of tumors that make up the most common type of primary malignant brain tumor. ... Full text Cite

EPID-25. Molecular Epidemiology of Adult Diffuse Gliomas in the United States

Conference Neuro-Oncology · November 11, 2025 AbstractINTRODUCTIONUS cancer registries recently started collecting data on brain molecular markers, providing for the first t ... Full text Cite

RADT-33. PROGNOSTIC AND PREDICTIVE EFFECT OF AGE IN MOLECULARLY-DEFINED LOWER GRADE GLIOMAS: A REPORT FROM THE PROSPECTIVE GLIOMA RESEARCH (PROGRES) DATABASE

Conference Neuro-Oncology · November 11, 2025 AbstractPURPOSEAge over 40 years is commonly regarded as a “high risk” feature and potential indication for adjuvant chemoradio ... Full text Cite

EPID-07. Treatment with gabapentin associated with improved survival in elderly glioblastoma patients

Conference Neuro-Oncology · November 11, 2025 AbstractGlioblastoma’hijacks’ neuronal pathways to drive tumor growth, and drugs affecting the function of these pathways may potentiate survival gains. Prior studies suggest a clinical benefit with using ... Full text Cite

EPID-05. Incidence of glioma varies significantly by global region

Conference Neuro-Oncology · November 11, 2025 AbstractBrain and other central nervous system (CNS) tumors are a significant source of global morbidity and mortality. Despite decades of epidemiological research, there are few known risk factors for th ... Full text Cite

IMMU-08. Metabolic reprogramming of CD8+ T-Cells by DPP-4 inhibition for glioblastoma immunotherapy

Conference Neuro-Oncology · November 11, 2025 AbstractGlioblastoma (GBM) is characterized by T cell exclusion and exhaustion. Therefore, there is a pressing need to identify molecular targets for improved T cell response in GBM. We recently showed th ... Full text Cite

EPID-06. The Key LARGO study: Building an international resource for glioblastoma epidemiology

Conference Neuro-Oncology · November 11, 2025 AbstractDespite decades of epidemiological research, no glioblastoma risk factors have been identified that explain substantial risk. Prior studies often rely on single- or multi-center recruitment, which ... Full text Cite

IMMU-81. Glioblastoma and other intracranial pathologies elicit systemic sympathetic hyperactivity that limits immunotherapeutic responses

Conference Neuro-Oncology · November 11, 2025 AbstractImmunotherapies remain largely ineffective against intracranial malignancies such as glioblastoma (GBM), in part due to profound systemic and local immune dysfunction. Hallmarks of systemic immune ... Full text Cite

INNV-37. Real-world observation rates and treatment patterns in IDH-mutated glioma: implications for targeted therapy use

Conference Neuro-Oncology · November 11, 2025 AbstractINTRODUCTIONThe approval of vorasidenib marks a paradigm shift in the management of IDH-mutated (mIDH) gliomas. This st ... Full text Cite

P14.21.B IMPACTS OF SEX AND RACE/ETHNICITY ON INCIDENCE OF VESTIBULAR SCHWANNOMA ACROSS THE LIFESPAN IN THE UNITED STATES

Conference Neuro-Oncology · October 3, 2025 AbstractBACKGROUNDVestibular schwannomas (VS) are benign tumors arising in the vestibulocochlear nerve. Previous research has identifi ... Full text Cite

Disparities in glioblastoma care: Insights from a nationwide survey.

Conference Journal of Clinical Oncology · June 2025 11112Background: Glioblastoma (GBM) care requires specialized, multidisciplinary management, often creating barriers to healt ... Full text Cite

EPID-16. GENOMIC ANCESTRY-RELATED RISK RATIOS FOR GLIOBLASTOMA INCIDENCE AMONG GLOBAL POPULATIONS AND RACIAL/ETHNIC GROUPS WITHIN THE UNITED STATES

Conference Neuro-Oncology · November 11, 2024 AbstractGlioblastoma (GBM) incidence varies globally, elevated rates in Europe and lower rates in Asia, Latin America, and Africa. While partially attributable to national differences in cancer diagnosis and ... Full text Cite

EPID-05. THE INCREASED RISK OF MENINGIOMA AMONG INDIVIDUALS WHO ARE NON-HISPANIC BLACK IS MAGNIFIED AMONG MALES AND AMONG THOSE DIAGNOSED WITH GRADE 2-3 TUMORS

Conference Neuro-Oncology · November 11, 2024 AbstractBACKGROUNDDemographic factors associated with elevated meningioma incidence include older age, female sex, and Black race. The ... Full text Cite

EPID-23. HISTORY OF TYPE III IMMUNE HYPERSENSITIVITY IMPROVES SURVIVAL IN GLIOBLASTOMA

Conference Neuro-Oncology · November 11, 2024 AbstractPreexisting atopy, particularly allergic rhinitis, is consistently associated with decreased risk of glioma, and there is evidence that preexisting autoimmune conditions may also decrease risk. Gliob ... Full text Cite

IMMU-09. REVERSING SYSTEMIC T CELL DYSFUNCTION TO LICENSE IMMUNOTHERAPY IN INTRACRANIAL TUMORS

Conference Neuro-Oncology · November 11, 2024 AbstractIntracranial tumors present unique challenges for immunotherapy. These can include both local and systemic modes of immune suppression, the mechanistic underpinnings of which are incompletely underst ... Full text Cite

EPCO-58. INTEGRATIVE PROTEOGENOMIC ANALYSES REVEAL INSIGHTS INTO SUBTYPE-SPECIFIC GLIOMA RISK

Conference Neuro-Oncology · November 11, 2024 AbstractGliomas are heterogeneous brain tumors with prognostically-significant subtypes and few risk factors. IDH-wildtype glioblastoma, the most common subtype, carries a dismal prognosis. Using the largest ... Full text Cite

DISP-08. GBM PATIENTS FACE TTF ACCESS AND INFORMATION INEQUITY THAT MAY IMPACT PATIENT OUTCOMES AND QUALITY-OF-LIFE

Conference Neuro-Oncology · November 11, 2024 AbstractWe evaluated the quality and accessibility of healthcare for Glioblastoma (GBM) patients across the United States through an online survey distributed to the OurBrainBank community and partners and p ... Full text Cite

P25.01.B ASSOCIATION BETWEEN EXPOSURE TO AIR POLLUTION AND BRAIN TUMOR INCIDENCE IN THE UNITED STATES

Conference Neuro-Oncology · October 17, 2024 AbstractBACKGROUNDAir pollution contains known human carcinogens. Prior studies evaluating an association between pollution exposure a ... Full text Cite

EPID-01. ESTIMATING THE BURDEN DUE TO BRAIN AND OTHER CNS TUMORS IN ADOLESCENTS IN THE UNITED STATES

Conference Neuro-Oncology · June 18, 2024 AbstractBACKGROUNDBrain and other central nervous system (CNS) tumors in adolescents have unique biological and behavioral distinction ... Full text Cite

Abstract PR-001: Beta-adrenergic blockade licenses the use of immunotherapy in primary brain tumors and brain metastases

Conference Cancer Research · March 4, 2024 AbstractImmunotherapy is less effective against intracranial metastases compared to extracranial metastases and ineffective against primary brain tumors such as glioblastoma. Brain tumors present a unique ch ... Full text Cite

BRAIN TUMORS IN UNITED STATES MILITARY VETERANS

Conference NEURO-ONCOLOGY · November 2023 Link to item Cite

P21.05.B CAPTURING EVOLVING DEFINITIONS OF 12 SELECT RARE CNS TUMORS: A TIMELY REPORT FROM CBTRUS AND NCI-CONNECT

Conference Neuro-Oncology · September 8, 2023 AbstractBACKGROUNDHistopathology-specific incidence, prevalence, and survival are essential population-based cancer statistics that de ... Full text Cite

P21.04.A IMPROVEMENTS IN SURVIVAL FOR GLIOBLASTOMA IN THE POST-STUPP PROTOCOL ERA

Conference Neuro-Oncology · September 8, 2023 AbstractBACKGROUNDThe Stupp protocol was accepted as standard of care for glioblastoma in 2005, and has led to significant increases i ... Full text Cite

Combination beta-adrenergic blockade and immunotherapy for the treatment of primary and metastatic brain cancer.

Conference Journal of Clinical Oncology · June 1, 2023 e14017 Background: Brain tumors present a unique challenge to immunotherapeutic success, as immune responses in patients with brain tumors are suppressed both within the tumor microenvironment and peripherally. The systemic immun ... Full text Cite

Mortality trends in primary malignant brain and central nervous system tumors vary by histopathology, age, race, and sex.

Conference J Neurooncol · March 2023 PURPOSE: Primary malignant brain and other central nervous system tumors are rare cancers that have shown rising mortality rates in recent years. To elucidate potential factors involved in this rising death rate, we examined mortality trends for primary ma ... Full text Link to item Cite

EPID-26. ALIGNING THE CBTRUS HISTOLOGY GROUPS WITH 2016 WHO CLASSIFICATION OF TUMORS OF THE CENTRAL NERVOUS SYSTEM

Conference Neuro-Oncology · November 12, 2021 AbstractBACKGROUNDThe Central Brain Tumor Registry of the United States (CBTRUS) uses a histology grouping scheme modeled after the Wo ... Full text Cite

EPID-11. A POPULATION STUDY OF CLINICAL TRIAL ACCRUAL FOR WOMEN AND MINORITIES IN NEURO-ONCOLOGY FOLLOWING THE NIH REVITALIZATION ACT

Conference Neuro-Oncology · November 12, 2021 AbstractINTRODUCTIONThe NIH Revitalization Act, implemented 29 years ago, set to improve the representation of women and minorities in ... Full text Cite

EPID-09. VARIATION IN GLIOMA INCIDENCE AMONG US HISPANICS BY GEOGRAPHIC REGION OF ORIGIN

Conference Neuro-Oncology · November 12, 2021 AbstractBACKGROUNDGlioma incidence is 25% lower in U.S. Hispanics than in White non-Hispanics. The US Hispanic population is diverse a ... Full text Cite

EPID-06. ASSOCIATIONS BETWEEN GERMLINE GENETIC VARIANTS AND OVERALL SURVIVAL IN PATIENTS WITH GLIOMA

Conference Neuro-Oncology · November 12, 2021 AbstractBACKGROUNDIn addition to somatic genetic variation in tumors, germline genetic variation can better define cancer susceptibili ... Full text Cite

BIOM-17. DIFFERENCES IN THE IMMUNE MICROENVIRONMENT OF GLIOMAS HARBORING IDH2 VERSUS IDH1 MUTATIONS

Conference Neuro-Oncology · November 12, 2021 AbstractINTRODUCTIONIDH mutations are a defining feature of lower-grade glioma and secondary glioblastoma. Approximately 95% of glioma ... Full text Cite

Epidemiologic Evaluation of Clinical Outcomes in Ethnic Minorities with Myelodysplastic Syndromes

Conference Blood · November 5, 2021 AbstractIntroduction:Myelodysplastic syndromes (MDS) are a spectrum of disorders with variable degrees of cytopenias, morphological dysplasia and risk of progression to acute ... Full text Cite

The state of neuro-oncology during the COVID-19 pandemic: A worldwide assessment

Conference Neuro Oncology Advances · January 1, 2021 Background:It remains unknown how the COVID-19 pandemic has changed neuro-oncology clinical practice, training, and research efforts. Methods:We performed an international survey of practitioners, scientists, and trainees from 21 neuro-oncology organizatio ... Full text Cite

Abstract 2327: Genetic correlation analysis identifies glioma heritability enrichment in immune cell types and novel protective associations with auto-immune conditions

Conference Cancer Research · August 15, 2020 AbstractIntroduction: Prior epidemiological studies in glioma have identified 25 germline risk variants, as well as risk association with exposure to ionizing radiation and protective association with histor ... Full text Cite

Abstract 2745: Tumor microenvironment and host genetics impact glioma progression in a Collaborative Cross-based orthotopic allograft model

Conference Cancer Research · July 1, 2019 AbstractGliomas are diffusely invasive brain tumors with fatal outcomes and few effective treatments. Precision medicine focuses on targeting the genetics of individual tumors, but not host genetics, desp ... Full text Cite

Abstract 4173: Previously identified common glioma risk SNPs are associated with familial glioma

Conference Cancer Research · July 1, 2019 AbstractBACKGROUND: Approximately 5% of gliomas occur in individuals with a family history of glioma, and first-degree relatives of brain tumor cases have a two-fold increase in risk of brain tumor. Recen ... Full text Cite

Esthesioneuroblastoma: Descriptive Epidemiology from the Central Brain Tumor Registry of the United States

Conference Journal of Neurological Surgery Part B: Skull Base · February 2019 Full text Cite

Abstract 4220: Heterogeneous distribution of prognostic protein markers in glioblastoma

Conference Cancer Research · July 1, 2018 AbstractBackground: Glioblastoma (GBM) is the most common and lethal primary malignant brain tumor in adults. The heterogeneity of the disease leads to significant variability in response to standard therapy ... Full text Cite

Abstract 233: Evaluating glioma risk associated with extent of European admixture in African-Americans and Latinos

Conference Cancer Research · July 1, 2018 AbstractGlioma incidence is highest in non-Hispanic Whites, where it occurs ~2x as frequently compared with other race/ethnicity groups. Glioma GWAS to date have included European ancestry populations only, ... Full text Cite

Abstract 1315: Estimating sex-specific effects of genetic loci associated with glioma risk

Conference Cancer Research · July 1, 2017 AbstractBACKGROUND: Incidence of glioma varies significantly by sex, and most glioma histologies occur with greater incidence in males. Previous analyses have examined the impact of estrogen exposure as a ri ... Full text Cite

Abstract 1302: Genome-wide association study of glioma reveals specific differences in genetic susceptibility to glioblastoma and non-glioblastoma

Conference Cancer Research · July 1, 2017 AbstractBACKGROUND: Glioma accounts for ~27% of all primary brain tumors and is responsible for ~13,000 cancer-related deaths in the US each year. Glioma tumors can be broadly classified into glioblastoma (G ... Full text Cite

Abstract 129: Integrated genomic analysis of survival outliers in glioblastoma

Conference Cancer Research · July 15, 2016 AbstractDespite the general poor prognosis for patients with GBM, a proportion survives well beyond the median survival of 12-14 months following diagnosis. To elucidate molecular features associated with di ... Full text Cite